#ModernaEarlyDisclosure

About ModernaEarlyDisclosure

Early disclosure of detailed Phase III data showed Moderna and Merck’s cancer vaccine plus Keytruda cut recurrence or death risk by 42% and distant metastasis or death risk by 38% in resected stage IIB-IV melanoma, both statistically significant. The trial had already met its primary endpoint, and Moderna shares had surged this year. Shares fell over 26% intraday, closing down ~17.6%. Positive results prompted a reassessment of how much optimism was already priced in.